Back to today’s briefing

Story perspectives

mRNA Vaccine, Keytruda Cut Melanoma Recurrence 49% Over Five Years

6/14/2026

48 4 Full Breakdown

Summary

Story summary

The mRNA vaccine plus KEYTRUDA cut melanoma recurrence or death risk by 49 % and gave five-year protection in a phase 2b study presented at ASCO in Chicago.
The trial followed 157 stage 3/4 melanoma patients after surgery for five years, noting fatigue, injection-site pain, chills, fever and headache as common side effects.
Merck and Moderna will confirm the findings in a phase 3 trial and seek INTerpath data for other cancers.

1 of 1

Story summary

The mRNA vaccine plus KEYTRUDA cut melanoma recurrence or death risk by 49 % and gave five-year protection in a phase 2b study presented at ASCO in Chicago.
The trial followed 157 stage 3/4 melanoma patients after surgery for five years, noting fatigue, injection-site pain, chills, fever and headache as common side effects.
Merck and Moderna will confirm the findings in a phase 3 trial and seek INTerpath data for other cancers.